VIM and ovarian carcinoma: In addition to our previous study showing that vimentin was downregulated in cisplatin-resistant cells, vimentin downregulation was also present in ovarian cancer cells with acquired resistance to two tubulin-targeting drugs, peloruside A and laulimalide [23], suggesting that vimentin silencing promotes drug resistance in ovarian cancer cells.